Bayer looks to JVs, not buys, for Indian growth

After Bayer set out disappointing earnings targets for the next two years, Bayer CFO Werner Baumann told Reuters one of his strategies for fighting back--without betting the farm in the process. Like other Big Pharma firms, Bayer is eyeing emerging markets as a source of growth now that Western markets have started to stagnate. But with so many drugmakers looking to grab share of the same fast-growing markets--China, India, Brazil and the like--acquisitions have grown expensive, Baumann said. Story